SA520411325B1 - مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها - Google Patents
مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتهاInfo
- Publication number
- SA520411325B1 SA520411325B1 SA520411325A SA520411325A SA520411325B1 SA 520411325 B1 SA520411325 B1 SA 520411325B1 SA 520411325 A SA520411325 A SA 520411325A SA 520411325 A SA520411325 A SA 520411325A SA 520411325 B1 SA520411325 B1 SA 520411325B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- oxoisoindolin
- piperidine
- ikzf2
- dione derivatives
- tautomer
- Prior art date
Links
- WENKGSGGXGQHSH-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical class C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O WENKGSGGXGQHSH-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 abstract 3
- 102100037796 Zinc finger protein Helios Human genes 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 101000599046 Homo sapiens Zinc finger protein Eos Proteins 0.000 abstract 1
- 102100037793 Zinc finger protein Eos Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549225P | 2017-08-23 | 2017-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA520411325B1 true SA520411325B1 (ar) | 2022-06-13 |
Family
ID=63638171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA520411325A SA520411325B1 (ar) | 2017-08-23 | 2020-02-20 | مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها |
Country Status (38)
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| JP2021521192A (ja) * | 2018-04-13 | 2021-08-26 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | セレブロンリガンドおよび同リガンドを含む二機能性化合物 |
| BR112020026947B1 (pt) * | 2018-07-10 | 2022-11-22 | Novartis Ag | Derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, e composição farmacêutica |
| AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| KR20210098960A (ko) | 2018-12-03 | 2021-08-11 | 다나-파버 캔서 인스티튜트 인크. | Helios의 소분자 분해제 및 사용 방법 |
| BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
| AU2020222346B2 (en) * | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2020165833A1 (en) * | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CA3252762A1 (en) * | 2019-04-12 | 2025-07-08 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| MX2021014443A (es) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
| US11458149B1 (en) | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| BR112022007867A2 (pt) * | 2019-10-30 | 2022-07-12 | Dana Farber Cancer Inst Inc | Degradadores de pequena molécula de helios e métodos de uso |
| CN110862395B (zh) * | 2019-11-13 | 2020-09-29 | 株洲千金药业股份有限公司 | 一种制备他达拉非重要杂质的原料化合物的制备方法 |
| MX2022005839A (es) * | 2019-11-19 | 2022-06-09 | Bristol Myers Squibb Co | Compuestos utiles como inhibidores de la proteina helios. |
| TW202140441A (zh) * | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| CA3177252A1 (en) * | 2020-04-30 | 2021-11-04 | Xiaobao Yang | Heterocycle and glutarimide skeleton-based compounds and applications thereof |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| WO2022007903A1 (zh) * | 2020-07-09 | 2022-01-13 | 四川海思科制药有限公司 | 一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用 |
| US20230271940A1 (en) * | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20240294489A1 (en) * | 2020-08-03 | 2024-09-05 | Captor Therapeutics S.A. | Low molecular weight protein degraders and their applications |
| KR102499522B1 (ko) | 2020-09-23 | 2023-02-13 | 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 | 세레브론 단백질의 조절제로서의 치환된 n-(2-(2,6-디옥소피페리딘-3-일)-1,3-디옥소이소인돌린-5-일)아릴설폰아미드 유사체 |
| WO2022073469A1 (en) * | 2020-10-07 | 2022-04-14 | Cullgen (Shanghai) , Inc. | Compounds and methods of treating cancers |
| JP2023545508A (ja) * | 2020-10-14 | 2023-10-30 | シーフォー セラピューティクス， インコーポレイテッド | Ｉｋｚｆ２又はｉｋｚｆ４を分解する三環式リガンド |
| CN116669769A (zh) * | 2020-10-16 | 2023-08-29 | 达纳－法伯癌症研究所公司 | Helios的哌啶基小分子降解剂和使用方法 |
| CA3192393A1 (en) * | 2020-10-16 | 2022-04-21 | Hu Liu | Piperidinyl small molecule degraders of helios and methods of use |
| WO2022120355A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| UY39671A (es) * | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
| WO2022216644A1 (en) | 2021-04-06 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds |
| CA3209633A1 (en) * | 2021-04-29 | 2022-11-03 | Tinghu Zhang | Phthalimido cereblon complex binders and transcription factor degraders and methods of use |
| US20240239785A1 (en) * | 2021-04-29 | 2024-07-18 | Neomorph, Inc. | Substituted 2-(2,6-dioxopiperidin-3-yl)-5-(1-piperidin-4-yl)isoindoline-1,3-dione derivatives and uses thereof |
| JP2024529298A (ja) | 2021-07-09 | 2024-08-06 | プレキシウム インコーポレイテッド | Ｉｋｚｆ２を調節するアリール化合物及び医薬組成物 |
| CA3223636A1 (en) | 2021-08-06 | 2023-02-09 | Christopher Walton CARROLL | Compositions and methods for selective degradation of engineered proteins |
| WO2023016518A1 (zh) * | 2021-08-11 | 2023-02-16 | 四川海思科制药有限公司 | 一种杂环衍生物及其组合物和药学上的应用 |
| CA3235512A1 (en) * | 2021-10-22 | 2023-04-27 | Xiaobao Yang | Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| US11919869B2 (en) | 2021-10-29 | 2024-03-05 | Gilead Sciences, Inc. | CD73 compounds |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| CA3237577A1 (en) * | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CN116640122A (zh) * | 2022-02-16 | 2023-08-25 | 苏州国匡医药科技有限公司 | Ikzf2降解剂及包含其的药物组合物和用途 |
| ES2999273T3 (en) | 2022-03-17 | 2025-02-25 | Gilead Sciences Inc | Ikaros zinc finger family degraders and uses thereof |
| US20250215012A1 (en) * | 2022-03-25 | 2025-07-03 | Regents Of The University Of Michigan | Ikzf2 degraders and uses thereof |
| KR20250024899A (ko) * | 2022-03-25 | 2025-02-20 | 온코피아 테라퓨틱스, 인코퍼레이티드. 디/비/에이/ 에스케이 라이프 사이언스 랩스 | Ikzf2 분해제로서의 바이사이클릭 헤테로아릴 함유 화합물 |
| WO2023201012A1 (en) * | 2022-04-15 | 2023-10-19 | Regents Of The University Of Michigan | Ikzf2 degraders and uses thereof |
| KR20250004824A (ko) | 2022-04-21 | 2025-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Kras g12d 조절 화합물 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4570792A1 (en) * | 2022-08-10 | 2025-06-18 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | Compound based on isoindoline-substituted glutarimide backbone and use thereof |
| WO2024059107A1 (en) * | 2022-09-14 | 2024-03-21 | President And Fellows Of Harvard College | Ikzf2 and ck1-alpha degrading compounds and uses thereof |
| CN120322222A (zh) * | 2022-12-07 | 2025-07-15 | 杭州格博生物医药有限公司 | 一种固体分散体、其制备方法和应用 |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024162746A1 (ko) | 2023-01-31 | 2024-08-08 | 한국화학연구원 | Ikzf2를 분해하는 인돌 화합물 및 이의 용도 |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025067466A1 (zh) * | 2023-09-28 | 2025-04-03 | 杭州多域生物技术有限公司 | 一种杂环化合物、其组合物及应用 |
| WO2025076284A1 (en) * | 2023-10-06 | 2025-04-10 | Delphia Therapeutics, Inc. | Compounds, pharmaceutical compositions thereof, and methods of using the same |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025113643A1 (en) | 2023-12-01 | 2025-06-05 | Gilead Sciences Inc. | Anti-fap-light fusion protein and use thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025245178A1 (en) * | 2024-05-21 | 2025-11-27 | Innovo Therapeutics, Inc. | Pak4, cstf2, or cstf2t protein degraders, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| US4818541A (en) | 1987-08-19 | 1989-04-04 | Schering Corporation | Transdermal delivery of enantiomers of phenylpropanolamine |
| US7196170B2 (en) | 1992-09-14 | 2007-03-27 | The General Hospital Corporation | Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| CA2624949C (en) | 1996-07-24 | 2011-02-15 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels |
| AU2001291195A1 (en) | 2000-12-01 | 2002-06-11 | Parker Hughes Institute | Nucleotide and protein sequence of helios 3 and methods of use |
| WO2002088122A1 (en) | 2001-04-26 | 2002-11-07 | Ajinomoto Co., Inc. | Heterocyclic compounds |
| AU2002323063B2 (en) | 2001-08-06 | 2007-11-08 | Entremed, Inc. | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040087558A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| US7612096B2 (en) | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
| US20070161696A1 (en) | 2004-04-23 | 2007-07-12 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| KR20070057907A (ko) * | 2004-09-03 | 2007-06-07 | 셀진 코포레이션 | 치환된 2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린의제조 방법 |
| JP4731867B2 (ja) | 2004-10-01 | 2011-07-27 | 国立大学法人三重大学 | Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法 |
| MX2007006439A (es) | 2004-12-01 | 2007-07-20 | Celgene Corp | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento de trastornos de inmunodeficiencia. |
| ATE481504T1 (de) | 2004-12-10 | 2010-10-15 | Siemens Healthcare Diagnostics | Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung |
| WO2007067500A2 (en) | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
| JP2009521931A (ja) | 2005-12-29 | 2009-06-11 | アントフロゲネシス コーポレーション | 胎盤幹細胞を収集及び保存するための改善された組成物、及び該組成物の使用方法 |
| JP2009533327A (ja) | 2006-03-22 | 2009-09-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 増殖性疾患を処置するためのｃ−ＭＥＴキナーゼ阻害剤 |
| US20070269827A1 (en) | 2006-05-18 | 2007-11-22 | Oklahoma Medical Research Foundation | Predicting and Diagnosing Patients With Autoimmune Disease |
| KR101342035B1 (ko) | 2006-06-20 | 2013-12-16 | 한국과학기술연구원 | 신장독성 및 부작용 유발 약물 검색용 바이오마커 및 이를이용한 신장독성 및 부작용 유발 약물 검색 방법 |
| US8877780B2 (en) * | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| JP2009092508A (ja) | 2007-10-09 | 2009-04-30 | Norihiro Nishimoto | リウマチ治療剤の効果の予測方法 |
| EP2227558A1 (en) | 2007-11-30 | 2010-09-15 | GlaxoSmithKline Biologicals SA | Method for classifying cancer patients as responder or non-responder to immunotherapy |
| KR100957051B1 (ko) | 2007-12-28 | 2010-05-13 | 한국과학기술연구원 | 니트로푸란토인 처리에 따른, 폐독성 유발 약물 검색용마커유전자 및 이를 이용한 검색 방법 |
| GB2456390A (en) | 2008-01-15 | 2009-07-22 | Glaxo Group Ltd | Bipolar disorder treatments |
| WO2009094592A2 (en) | 2008-01-23 | 2009-07-30 | Perlegen Sciences, Inc. | Genetic basis of alzheimer's disease and diagnosis and treatment thereof |
| WO2009117122A2 (en) | 2008-03-19 | 2009-09-24 | Existence Genetics Llc | Genetic analysis |
| WO2009137095A2 (en) | 2008-05-08 | 2009-11-12 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
| RU2012104214A (ru) | 2009-08-05 | 2013-09-10 | Верситек Лимитед | Противовирусные соединения и способы их получения и применения |
| US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| EP3272884A3 (en) | 2009-10-26 | 2018-02-14 | Abbott Molecular Inc. | Detection of chromosomal abnormalities associated with prognosis of non small cell lung cancer |
| AU2011253481A1 (en) | 2010-05-12 | 2013-01-10 | Steven E. Schutzer | Diagnostic markers for neuropsychiatric disease |
| US20120142701A1 (en) | 2010-05-28 | 2012-06-07 | The University Of Hong Kong | Compounds and methods for the treatment of proliferative diseases |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| US20130281304A1 (en) | 2010-08-13 | 2013-10-24 | Andrew P. Feinberg | Comprehensive Methylome Map of Myeloid and Lymphoid Commitment from Hematopoietic Proenitors |
| EP3514170A1 (en) | 2010-10-22 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | Discovery of regulatory t cells programmed to suppress an immune response |
| EP2717876B1 (en) | 2011-06-06 | 2018-12-19 | University of Iowa Research Foundation | Substances and compostions for use in methods of inhibiting muscle atrophy |
| US20140234342A1 (en) | 2011-06-21 | 2014-08-21 | Innate Pharma | Nkp46-mediated nk cell tuning |
| WO2013006474A2 (en) | 2011-07-01 | 2013-01-10 | Beckman Coulter, Inc. | Regulatory t cells and methods of identifying, obtaining and using to treat immuno-based disorders |
| CN103797120B (zh) | 2011-09-16 | 2017-04-12 | 上海长海医院 | 前列腺癌的生物学标志物、治疗靶点及其用途 |
| US10238694B2 (en) | 2011-12-01 | 2019-03-26 | The University Of Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory T cells |
| US9481866B2 (en) | 2011-12-16 | 2016-11-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T cell populations enriched for stable regulatory T-cells |
| WO2013098797A2 (en) | 2011-12-31 | 2013-07-04 | Kuriakose Moni Abraham | Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer |
| CN104245923B (zh) | 2012-03-02 | 2018-04-20 | 加州大学评议会 | 同种异型抗原‑反应性调节t细胞的增殖 |
| GB201207297D0 (en) | 2012-04-26 | 2012-06-06 | Senzagen Ab | Analytical methods and arrays for use in the same |
| GB201213571D0 (en) | 2012-07-31 | 2012-09-12 | Univ Leuven Kath | Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal |
| EP2682750A1 (en) | 2012-07-02 | 2014-01-08 | Sotio a.s. | In vitro method for the diagnosis and surveillance of cancer |
| ES2776029T3 (es) | 2012-10-08 | 2020-07-28 | St Jude Childrens Res Hospital | Terapias basadas en el control de la estabilidad y función de las células T reguladoras por medio de un eje neuropilina-1:semaforina |
| WO2014122467A1 (en) | 2013-02-06 | 2014-08-14 | Loxbridge Research Llp | Systems and methods for early disease detection and real-time disease monitoring |
| CA2906752A1 (en) | 2013-03-14 | 2014-09-25 | Children's Medical Center Corporation | Compositions and methods for reprogramming hematopoietic stem cell lineages |
| BR112015022490A2 (pt) | 2013-03-15 | 2017-07-18 | Veracyte Inc | métodos e composições para classificação de amostras |
| US20160122821A1 (en) | 2013-06-10 | 2016-05-05 | Suregene, Llc | Genetic markers of antipsychotic response |
| CA2923700A1 (en) | 2013-09-09 | 2015-03-12 | The Scripps Research Institute | Methods and systems for analysis of organ transplantation |
| US10927412B2 (en) | 2013-10-01 | 2021-02-23 | The Regents Of The University Of California | Endometriosis classifier |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| WO2015107196A1 (en) | 2014-01-20 | 2015-07-23 | Institut Curie | Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation |
| EP4649963A2 (en) * | 2014-04-14 | 2025-11-19 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20160058872A1 (en) * | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| CA2967447C (en) | 2014-12-05 | 2025-07-08 | Foundation Medicine, Inc. | MULTIGEN ANALYSIS OF TUMOR SAMPLES |
| EP3034620A1 (en) | 2014-12-17 | 2016-06-22 | Diaxonhit | Compositions and methods for diagnosing thyroid cancer |
| WO2016103269A1 (en) | 2014-12-23 | 2016-06-30 | Ramot At Tel-Aviv University Ltd. | Populations of neural progenitor cells and methods of producing and using same |
| WO2016118638A1 (en) | 2015-01-20 | 2016-07-28 | Merial Inc. | Anthelmintic compounds, compositions and method of using thereof |
| EP3050570A1 (en) | 2015-01-31 | 2016-08-03 | Neurovision Pharma GmbH | Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF |
| WO2016140974A1 (en) | 2015-03-01 | 2016-09-09 | Novena Therapeutics Inc. | Process for measuring tumor response to an initial oncology treatment |
| US9822098B2 (en) | 2015-05-22 | 2017-11-21 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| US10338077B2 (en) | 2015-06-02 | 2019-07-02 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins |
| CA2988119A1 (en) | 2015-06-03 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy |
| JP2018519295A (ja) | 2015-06-22 | 2018-07-19 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 粘膜固有層調節性ｔ細胞の誘導 |
| WO2017042337A1 (en) | 2015-09-09 | 2017-03-16 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmhotz-Gemeinschaft | Short-chain fatty acids for use in the treatment of cardiovascular disease |
| US20180250369A1 (en) | 2015-09-11 | 2018-09-06 | Ventria Bioscience, Inc. | Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases |
| WO2017058881A1 (en) | 2015-09-28 | 2017-04-06 | The Trustees Of Columbia University In The City Of New York | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma |
| KR102838444B1 (ko) | 2015-09-30 | 2025-07-24 | 더 유니버시티 코트 오브 더 유니버시티 오브 애버딘 | 탈리도마이드 유사체 및 사용 방법 |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| US11090373B2 (en) | 2015-12-04 | 2021-08-17 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Antigen-specific T cells for inducing immune tolerance |
| AU2017235461B2 (en) | 2016-03-15 | 2023-02-23 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| CA3020281A1 (en) | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| PL3660004T3 (pl) | 2016-10-11 | 2023-10-02 | Arvinas Operations, Inc. | Związki i sposoby do ukierunkowanej degradacji receptora androgenowego |
| WO2018119448A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| EP3573977A4 (en) | 2017-01-26 | 2020-12-23 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| CN106932576A (zh) | 2017-03-22 | 2017-07-07 | 山东大学深圳研究院 | 一种人调节性t细胞的免疫抑制功能的检测方法 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
-
2018
- 2018-08-21 TW TW107129068A patent/TWI793151B/zh not_active IP Right Cessation
- 2018-08-22 AR ARP180102390 patent/AR112529A1/es not_active Application Discontinuation
- 2018-08-22 US US16/108,713 patent/US10414755B2/en active Active
- 2018-08-22 UY UY0001037854A patent/UY37854A/es not_active Application Discontinuation
- 2018-08-23 JP JP2020510565A patent/JP7386787B2/ja active Active
- 2018-08-23 KR KR1020207007884A patent/KR20200044038A/ko not_active Ceased
- 2018-08-23 HR HRP20230244TT patent/HRP20230244T1/hr unknown
- 2018-08-23 HU HUE18772885A patent/HUE061895T2/hu unknown
- 2018-08-23 JO JOP/2020/0042A patent/JOP20200042A1/ar unknown
- 2018-08-23 RS RS20230203A patent/RS64058B9/sr unknown
- 2018-08-23 FI FIEP18772885.2T patent/FI3672949T3/fi active
- 2018-08-23 WO PCT/IB2018/056400 patent/WO2019038717A1/en not_active Ceased
- 2018-08-23 PL PL18772885.2T patent/PL3672949T3/pl unknown
- 2018-08-23 SI SI201830871T patent/SI3672949T1/sl unknown
- 2018-08-23 EP EP22213789.5A patent/EP4183782A1/en not_active Withdrawn
- 2018-08-23 PT PT187728852T patent/PT3672949T/pt unknown
- 2018-08-23 AU AU2018319577A patent/AU2018319577B2/en not_active Ceased
- 2018-08-23 ES ES18772885T patent/ES2940448T3/es active Active
- 2018-08-23 CR CR20200081A patent/CR20200081A/es unknown
- 2018-08-23 CU CU2020000014A patent/CU20200014A7/es unknown
- 2018-08-23 EA EA202090553A patent/EA202090553A1/ru unknown
- 2018-08-23 SG SG11202000490PA patent/SG11202000490PA/en unknown
- 2018-08-23 CN CN201880053653.2A patent/CN111051298B/zh active Active
- 2018-08-23 MA MA49952A patent/MA49952B1/fr unknown
- 2018-08-23 PE PE2020000271A patent/PE20200796A1/es unknown
- 2018-08-23 DK DK18772885.2T patent/DK3672949T5/da active
- 2018-08-23 BR BR112020003373-1A patent/BR112020003373B1/pt not_active IP Right Cessation
- 2018-08-23 CA CA3072694A patent/CA3072694A1/en active Pending
- 2018-08-23 EP EP18772885.2A patent/EP3672949B9/en active Active
- 2018-08-23 LT LTEPPCT/IB2018/056400T patent/LT3672949T/lt unknown
- 2018-08-23 MX MX2020002060A patent/MX2020002060A/es unknown
-
2019
- 2019-08-05 US US16/532,118 patent/US10647701B2/en not_active Expired - Fee Related
- 2019-08-05 US US16/532,106 patent/US10640489B2/en active Active
-
2020
- 2020-01-13 ZA ZA2020/00208A patent/ZA202000208B/en unknown
- 2020-01-17 PH PH12020500125A patent/PH12020500125A1/en unknown
- 2020-02-18 IL IL272748A patent/IL272748B2/en unknown
- 2020-02-20 CO CONC2020/0001860A patent/CO2020001860A2/es unknown
- 2020-02-20 CL CL2020000427A patent/CL2020000427A1/es unknown
- 2020-02-20 SA SA520411325A patent/SA520411325B1/ar unknown
- 2020-02-20 DO DO2020000037A patent/DOP2020000037A/es unknown
- 2020-02-20 EC ECSENADI202013248A patent/ECSP20013248A/es unknown
- 2020-03-31 US US16/835,938 patent/US11053218B2/en not_active Expired - Fee Related
- 2020-11-26 AU AU2020277231A patent/AU2020277231A1/en not_active Abandoned
-
2021
- 2021-06-09 US US17/343,016 patent/US20210309638A1/en not_active Abandoned
-
2022
- 2022-09-13 AU AU2022231670A patent/AU2022231670A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520411325B1 (ar) | مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها | |
| MX2021000310A (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de las enfermedades que dependen de la familia de dedo de zinc ikaros (ikzf2). | |
| PH12021550045A1 (en) | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| PH12019500395A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
| TN2018000130A1 (en) | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
| JOP20180094A1 (ar) | مركب حلقي غير متجانس كمثبط بروتين كيناز | |
| MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
| PH12016501651A1 (en) | Triazine compound and use thereof for medical purposes | |
| TN2017000158A1 (en) | Carbazole derivatives | |
| PH12022551226A1 (en) | Pyrrolotriazine compounds acting as mnk inhibitor | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| CO6361991A2 (es) | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos. | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| WO2021015294A3 (en) | Combination therapy for cancer treatment | |
| WO2020232330A8 (en) | Inhibiting agents for bruton's tyrosine kinase | |
| MX2020009334A (es) | Compuestos para tratar la enfermedad de alzheimer. | |
| EA202190213A1 (ru) | Производные 3-(5-гидрокси-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и их применение в лечении заболеваний, связанных с белком с "цинковыми пальцами" 2 (ikzf2) семейства ikaros | |
| NZ801355A (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
| UA104725C2 (ru) | Серосодержащая гетероциклическая производная, имеющая ингибирующую активность бета-секретазы |